Programmed cell death 1 (PD-1) inhibition has demonstrated a significant and prolonged survival benefit for patients with advanced ESCC in numerous clinical studies, such as KEYNOTE-590, KEYNOTE-181, and Checkmate-648 [9–11]. Here, PDCD1 is linked to esophageal squamous cell carcinoma.